Want to see TSE:CRDL full AI Analyst Report?
CRDL Stock Chart & Stats
C$1.67
-C$0.03(-1.80%)
At close: 4:00 PM EDT
C$1.67
-C$0.03(-1.80%)
Day’s Range― - ―
52-Week RangeC$1.23 - C$2.69
Previous CloseN/A
Volume111.36K
Average Volume (3M)136.50K
Market Cap
C$290.89M
Enterprise ValueC$145.28
Total Cash (Recent Filing)C$26.08M
Total Debt (Recent Filing)C$107.00K
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Nov 12, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding116,822,670
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$13.17Price Target Upside688.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt limits interest and refinancing pressure, preserving financial flexibility as Cardiol funds clinical development. This does not solve the company’s cash-burn problem, but it reduces balance-sheet risk relative to a similarly unprofitable biotech carrying substantial borrowings.
Focused Cardiovascular Development StrategyA concentrated focus on cardiovascular inflammation, fibrosis and heart failure can help direct limited resources toward defined therapeutic needs. The strategy provides a coherent development identity, although its long-term value still depends on clinical and regulatory success.
Losses Showed Modest ImprovementThe reduction in annual loss indicates some stabilization in reported profitability pressure, which could support better capital planning if sustained. However, the improvement is modest and the company remains substantially loss-making, so it is an incremental positive rather than evidence of operating breakeven.
Bears Say
Pre-Revenue Business ModelWithout meaningful product revenue, Cardiol has no established commercial engine to fund research, operations or future expansion. The company remains dependent on successful development, regulatory approval and eventual commercialization before it can demonstrate durable operating scale.
Persistent Cash BurnOngoing cash outflows mean Cardiol will likely require external funding or balance-sheet resources to continue clinical programs and operations. Because free cash flow deterioration accompanied substantial losses, the funding requirement is a structural feature of the current development-stage model.
Declining Equity And Asset BaseThe shrinking equity and asset base reflects cumulative losses and cash consumption, reducing the financial cushion available for multi-year clinical development. Even with very low debt, continued erosion can increase reliance on new capital and limit flexibility if trials or regulatory timelines extend.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.23 and its highest was C$2.69 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is C$290.89M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 85 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 12, 2026. The company reported -C$0.05 earnings per share for the quarter, beating the consensus estimate of -C$0.097 by C$0.047.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 116,822,670 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -C$0.05 in its last earnings report, beating expectations of -C$0.097. Following the earnings report the stock price went up 14.151%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$13.17 (688.79% Upside)
C$13.17 (688.79% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.62%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$13.17
▲(688.79% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―